Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and … [Read more…]

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab (HZN-7734), a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate-to-severe alopecia areata. Alopecia areata is a common, acute onset autoimmune disorder … [Read more…]

PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on Monday, May 23, 2022, at 10:45 a.m. Eastern Time. Investors and the general public are invited to access the live webcast of the fireside chat on … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022. The company will present a company overview and business update available for on-demand listening starting Tuesday, May 24, 2022, 7:00 a.m. Eastern Time that will … [Read more…]

─Customer Projects Bridging LGM Pharma’s API Sourcing and CDMO Services Range from Promising Pharmaceutical Start-Ups to a Top 5 Global Pharma Firm─ ─LGM Pharma Has Added More than 25 New Clients This Year and Fee-for-Service Revenues Have Almost Trebled Year-Over-Year─ ─Learn More About LGM Pharma’s Combination of API Sourcing and CDMO Services at Booth 1615 … [Read more…]

BROOMFIELD, Colo.–(BUSINESS WIRE)–Swisslog Healthcare, a top supplier in healthcare technology combining pharmacy and transport automation, has announced Dave Hartley as its new vice president of Customer Care for Swisslog Healthcare TransLogic. Previously serving as the director of Field Services for Swisslog Healthcare, Hartley is experienced in supporting the company’s commitment to making sure products meet … [Read more…]

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022. A presentation will be available on the Investor Relations section of the company’s … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Exo Therapeutics, Inc., a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery and Catherine Scholz, PharmD, as Senior Vice President, Program Management. “Drs. Ioannidis and Scholz are both dedicated … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference. … [Read more…]

LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the presentation of a late-breaking poster on data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma. The … [Read more…]